Want to see RXRX full AI Analyst Report?
Top Page
Recursion Pharmaceuticals
(NASDAQ:RXRX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$3.00
▼(-20.63% Downside)
Action:Reiterated
Date:07/17/26
RXRX’s score is held back primarily by weak financial performance (negative gross profit, very large losses, and persistent cash burn) and bearish technical trend signals (below major moving averages with weak momentum). These are partially offset by constructive earnings-call signals around cash runway, cost discipline, partnership monetization, and a growing set of upcoming clinical readouts that could improve the fundamental outlook if execution continues.
Positive Factors
Balance sheet & runway
A sizable cash balance and explicit runway into early 2028, together with a guided sub-$390M 2026 cash opex target and reported ~30% YoY opex reduction, materially extend the company’s ability to fund clinical programs and deliver catalysts over the next 12–18 months without immediate financing.
Negative Factors
Cash burn & weak cash flow
Persistent negative operating and free cash flow (TTM ~-$321M) means the business remains reliant on external funding or partner payments. Over the medium term this raises dilution and financing risk if milestone timing or partner inflows slip, constraining ability to expand programs or commercialize independently.
Read all positive and negative factors
Positive Factors
Negative Factors
Balance sheet & runway
A sizable cash balance and explicit runway into early 2028, together with a guided sub-$390M 2026 cash opex target and reported ~30% YoY opex reduction, materially extend the company’s ability to fund clinical programs and deliver catalysts over the next 12–18 months without immediate financing.
Read all positive factors
Recursion Pharmaceuticals Key Performance Indicators (KPIs)
Any
Revenue by Segment
Breaks down revenue by different business units or product lines, highlighting which areas are driving growth and which may need strategic adjustments. This insight helps assess the company's diversification and dependency on specific segments.
Breaks down revenue by different business units or product lines, highlighting which areas are driving growth and which may need strategic adjustments. This insight helps assess the company's diversification and dependency on specific segments.
Data provided by:
The Fly
The FlyRecursion Pharmaceuticals (RXRX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.56B
Dividend YieldN/A
Average Volume (3M)22.44M
Price to Earnings (P/E)―
Beta (1Y)3.28
Revenue Growth11.07%
EPS Growth32.35%
CountryUS
Employees600
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.20
Shares Outstanding524,677,860
10 Day Avg. Volume26,162,671
30 Day Avg. Volume22,443,950
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.62
Price to Sales (P/S)24.50
P/FCF Ratio-4.84
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$7.38Price Target Upside95.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.93
Revenue Forecast (FY)$59.12M
Recursion Pharmaceuticals Business Overview & Revenue Model
Company Description
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines...
How the Company Makes Money
Recursion primarily makes money through (1) collaboration and partnership revenue and (2) potential future product revenue from commercializing its own drug candidates (which is dependent on successful clinical development and regulatory approval)...
Recursion Pharmaceuticals Earnings Call Summary
Earnings Call Date:May 06, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 11, 2026
Earnings Call Sentiment Positive
The call emphasized multiple clear positives: a clinical proof of concept (REC-4881), encouraging early clinical safety/PK/PD for REC-1245, first patient dosed for REC-4539, strong partnership traction (> $500M inflows, 10 milestones), platform efficiency gains (≈90% fewer compounds, ~2x faster candidate progression), and a 30% YoY reduction in cash operating expenses with $665M cash (runway into early 2028). The primary negatives are that the programs are still early (key readouts and registrational plans pending), regulatory uncertainty for first-in-disease indications, potential safety risks as dose escalation continues, and a finite runway that could be pressured by delays. Overall, the highlights materially outweigh the lowlights given the combination of clinical proofs, platform progress, partnership milestones, and cost discipline.Positive Updates
Clinical Proof of Concept for REC-4881
REC-4881 (allosteric MEK1/2 inhibitor) achieved a clinical proof of concept in FAP with significant reduction in precancerous polyps and durable responses; FDA engagement for a potential registrational path has been initiated (engagement started H1 2026).
Negative Updates
No Approved Revenue-Generating Medicines Yet
Despite clinical POC and multiple programs in clinic, Recursion has not reported any approved, revenue-generating medicines—future commercial revenues depend on successful registrational outcomes and partner opt-ins.
Read all updates
Q1-2026 Updates
Positive
Negative
Clinical Proof of Concept for REC-4881
REC-4881 (allosteric MEK1/2 inhibitor) achieved a clinical proof of concept in FAP with significant reduction in precancerous polyps and durable responses; FDA engagement for a potential registrational path has been initiated (engagement started H1 2026).
Read all positive updates
Company Guidance
Management guided that Recursion closed the quarter with $665M in cash, which they say provides runway into early 2028, and reiterated 2026 cash operating expense guidance of < $390M after achieving a ~30% year‑over‑year reduction in operating expenses; platform monetization to date includes >$500M in partner inflows and 10 milestones delivered (including a fifth Sanofi milestone this quarter). They said the company has 5 wholly‑owned programs (each with inflection points over the next 12–18 months) and expects multiple clinical readouts for every clinical‑stage program in the next 12–18 months; specific clinical metrics include REC‑1245 (16 patients across 4 dose levels, 7/16 MSI‑high, no DLTs to date, ~90% grade 1–2 GI AEs, one grade 3 event, no treatment‑related SAEs, fuller PK/PD and dose‑escalation data expected H2 2026) and REC‑4539 (first patient dosed in April after ~20 months and ~400 compounds synthesized). Platform and R&D metrics highlighted include >50 petabytes of proprietary multimodal data, >10 high‑dimensional biology maps (over half with Roche/Genentech), claims of ~90% fewer compounds synthesized versus industry benchmarks (~330 vs 2,500–5,000) and ~2× faster progression to development candidates, plus ClinTech improvements of ~30–60% faster trial enrollment and increases in eligible patient populations from ~10% to ~40%.Recursion Pharmaceuticals Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
72
Positive
Cash Flow
24
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 66.29M | 74.68M | 58.84M | 43.88M | 39.68M | 10.00M |
| Gross Profit | -22.83M | -46.27M | 13.60M | 1.29M | -8.59M | 10.00M |
| EBITDA | -479.48M | -559.38M | -426.72M | -307.63M | -227.66M | -175.12M |
| Net Income | -559.78M | -644.76M | -463.66M | -328.07M | -239.48M | -186.48M |
Balance Sheet | ||||||
| Total Assets | 1.34B | 1.47B | 1.45B | 653.70M | 701.29M | 610.35M |
| Cash, Cash Equivalents and Short-Term Investments | 654.47M | 743.29M | 594.35M | 391.56M | 549.91M | 516.56M |
| Total Debt | 72.38M | 77.97M | 108.49M | 50.67M | 51.01M | 11.48M |
| Total Liabilities | 314.75M | 343.26M | 413.82M | 190.26M | 215.48M | 67.41M |
| Stockholders Equity | 1.02B | 1.13B | 1.03B | 463.44M | 485.81M | 542.94M |
Cash Flow | ||||||
| Free Cash Flow | -325.85M | -378.28M | -372.87M | -300.33M | -120.88M | -198.41M |
| Operating Cash Flow | -320.95M | -371.81M | -359.17M | -287.78M | -83.52M | -158.61M |
| Investing Cash Flow | -9.94M | -16.87M | 260.06M | -10.23M | 193.25M | -271.74M |
| Financing Cash Flow | 477.54M | 521.53M | 304.12M | 140.13M | 154.34M | 458.54M |
Recursion Pharmaceuticals Technical Analysis
Negative
3.78
Price Trends
3.32
Negative
3.37
Negative
4.03
Negative
Market Momentum
-0.04
Positive
35.55
Neutral
5.60
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For RXRX, the sentiment is Negative. The current price of 3.78 is above the 20-day moving average (MA) of 3.46, above the 50-day MA of 3.32, and below the 200-day MA of 4.03, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 35.55 is Neutral, neither overbought nor oversold. The STOCH value of 5.60 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for RXRX.
Recursion Pharmaceuticals Risk Analysis
Recursion Pharmaceuticals disclosed 107 risk factors in its most recent earnings report. Recursion Pharmaceuticals reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Recursion Pharmaceuticals Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | $3.56B | -1,433.85 | -1.41% | ― | 95.29% | 98.21% | |
63 Neutral | $3.67B | -16.69 | -24.26% | ― | 55.87% | 66.29% | |
55 Neutral | $2.36B | -5.53 | -34.11% | ― | 78.34% | -161.91% | |
54 Neutral | $1.56B | -2.41 | -54.32% | ― | 11.07% | 32.35% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $2.91B | -11.20 | -36.95% | ― | ― | -68.57% |
* Healthcare Sector Average
RXRX
Recursion Pharmaceuticals
2.89
-3.51
-54.84%
AGIO
Agios Pharma
40.06
0.14
0.35%
ADPT
Adaptive Biotechnologies
21.86
11.55
112.03%
ARQT
Arcutis Biotherapeutics
27.53
13.19
91.98%
IRON
Disc Medicine
74.38
15.00
25.26%
Recursion Pharmaceuticals Corporate Events
Executive/Board ChangesShareholder Meetings
Recursion Shareholders Reelect Directors and Approve Governance Matters
Positive
Jun 18, 2026
Recursion Pharmaceuticals, Inc. held its 2026 annual meeting of stockholders on June 17, 2026, where shareholders elected Najat Khan, Ph.D., and Franziska Michor, Ph.D., as Class II directors to serve until the 2029 annual meeting. The votes showe...
Business Operations and StrategyFinancial Disclosures
Recursion Highlights Q1 2026 Results and Pipeline Progress
Positive
May 6, 2026
On May 6, 2026, Recursion reported first-quarter 2026 results and business updates, highlighting multiple pipeline milestones and continued advancement of its AI-native Recursion OS platform. Early Phase 1/2 data for REC-1245, a potential first-in...
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Recursion Pharmaceuticals Announces Planned Board Leadership Transition
Neutral
Apr 30, 2026
On April 28, 2026, Recursion Pharmaceuticals announced that founder and Chair of the Board Christopher Gibson, Ph.D., informed the company he will not stand for re-election as a Class II director at the 2026 Annual Meeting of Stockholders. The com...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.